Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
AssigneeAlcon Inc.
InventorDavid Bingaman
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating ocular neovascularization, angiogenesis, retinal edema, diabetic retinopathy, and/or retinal ischemia in order to prevent the loss of visual acuity associated with such conditions. More specifically, the present invention provides compositions containing receptor tyrosine kinase (RTK) inhibitors having unique binding profiles and their use in treating ocular disorders.
Claims140
A method for inhibiting ocular neovascularization and retinal edema, said method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a receptor tyrosine kinase inhibitor that blocks tyrosine autophosphorylation of VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, Tie-2, PDGFR, c-KIT, Flt-3, and CSF-1R.
A method for causing regression of neovascularization, said method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a receptor tyrosine kinase inhibitor that blocks tyrosine autophosphorylation of VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, Tie-2, PDGFR, c-KIT, Flt-3, and CSF-1R.
A method for inhibiting retinal edema, said method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a receptor tyrosine kinase inhibitor that blocks tyrosine autophosphorylation of VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, Tie-2, PDGFR, c-KIT, Flt-3, and CSF-1R.
A method for inhibiting diabetic retinopathy, said method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a receptor tyrosine kinase inhibitor that blocks tyrosine autophosphorylation of VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, Tie-2, PDGFR, c-KIT, Flt-3, and CSF-1R.
A method for inhibiting sequela associated with retinal ischemia, said method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a receptor tyrosine kinase inhibitor that blocks tyrosine autophosphorylation of VEGF receptor 1, VEGF receptor 2, VEGF receptor 3, Tie-2, PDGFR, c-KIT, Flt-3, and CSF-1R.
Dependencies are inferred from the claim text.